Immunovia Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Philipp Mathieu
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.009% |
| Management average tenure | less than a year |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
CEO
Philipp Mathieu
less than a year
Tenure
Mr. Philipp Mathieu serves as Chief Executive Officer and President at Immunovia AB (publ) since June 02, 2022. Mr. Mathieu served as an Acting CEO & President of Immunovia AB (publ) since January 20, 2022...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & President | less than a year | no data | 0.0093% SEK 51.4k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Executive Officer of US | less than a year | no data | no data |
1.0yrs
Average Tenure
Experienced Management: IMMNOS's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of the Board | 16yrs | SEK 580.00k | 7.56% SEK 41.7m | |
| Independent Director | 6yrs | SEK 288.00k | 0.14% SEK 761.7k | |
| Member of Scientific Advisory Board | 6.6yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 6.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.5yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 2.7yrs | SEK 268.00k | 0.052% SEK 286.0k | |
| Director | 1.7yrs | SEK 160.00k | 0.0047% SEK 25.8k |
5.5yrs
Average Tenure
66yo
Average Age
Experienced Board: IMMNOS's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/28 06:54 |
| End of Day Share Price | 2022/10/31 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immunovia AB (publ) is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Juan Pedro Rodríguez Serrate | Edison Investment Research |
| Alexandru Cogut | Kempen & Co. NV |